HSBC Securities downgraded Illumina from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/12/2024 | $156.00 | Equal-Weight | Morgan Stanley |
| 10/17/2024 | $180.00 | Hold → Buy | HSBC Securities |
| 8/28/2024 | Hold → Buy | Argus | |
| 8/16/2024 | $120.00 → $154.00 | Neutral → Buy | Daiwa Securities |
| 8/14/2024 | $126.00 → $144.00 | Hold → Buy | TD Cowen |
| 8/14/2024 | $125.00 | Underweight → Equal Weight | Barclays |
| 7/10/2024 | $140.00 | Neutral → Buy | Citigroup |
| 6/3/2024 | $115.00 | Hold | Jefferies |
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. "We are pleased to expand o
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. Detailed plans for the pr
SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024 Healthcare Conference on November 20, 2024Fireside chat at 6:20am Pacific Time (9:20am Eastern Time)7th Annual Evercore HealthCONx Conference on December 3, 2024Fireside chat at 10:20am Pacific Time (1:20pm Eastern Time)For each conference, the webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
Morgan Stanley resumed coverage of Illumina with a rating of Equal-Weight and set a new price target of $156.00
HSBC Securities upgraded Illumina from Hold to Buy and set a new price target of $180.00
Argus upgraded Illumina from Hold to Buy
Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basisCore Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billionRaised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5%Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASD
SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November 4, 2024. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Monday, November 4, 2024. Interested parties may access the live teleconference through the Investor Info section
Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024Core Illumina GAAP operating margin of 40.5% and non-GAAP operating margin of 22.2% for Q2 2024Core Illumina GAAP diluted earnings per share of $0.41 and non-GAAP diluted earnings per share of $1.09 for Q2 2024Lowered fiscal year 2024 Core Illumina revenue guidance to decline 2% to 3% (down 1.5% to 2.5% in constant currency) from 2023Raised Core Illumina non-GAAP operating margin guidance to a range of 20.5% to 21% for fiscal year 2024Introducing guidance for Core Illumina non-GAAP diluted earnings per share in the range of $3.80 to $3.95 for fiscal year 2024O
4 - ILLUMINA, INC. (0001110803) (Issuer)
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.43% on an annualized basis producing an average annual return of 20.85%. Currently, Illumina has a market capitalization of $18.45 billion. Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $46,623.49 today based on a price of $115.79 for ILMN at the time of writing. Illumina's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine a
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual return of 21.1%. Currently, Illumina has a market capitalization of $18.49 billion. Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $4,729.97 today based on a price of $116.10 for ILMN at the time of writing. Illumina's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and re
Wednesday, Illumina Inc (NASDAQ:ILMN) acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research for an undisclosed consideration. Amid this M&A deal, 10x Genomics, Inc (NASDAQ:TXG) shares are trading lower. William Blair writes that Fluent’s PIPseq single-cell technology does not require an instrument, and costs per cell is at least 50% less than 10x and is the cheapest on the market, citing a recent bioRxiv preprint. William Blair highlights that cost reduction has become crucial in the increasingly crowded single-cell market. Bundled offerings will further strengthen Fluent’s competitive edge with low-cost positioning. While Illumina emphasize
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10. Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. He brings extensive commercial experience across the healthcare
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to